-60%

est. 2Y upside i

HealthcareSeries A

Rank

#1325

Sector

Biotechnology

Est. Liquidity

~3Y

Data Quality

Data: Medium

64x Bio presents a moderate upside opportunity for a job seeker, driven by its strong proprietary technology (VectorSelect™ and AAV Apex Suite) addressing a critical manufacturing bottleneck in the rapidly growing cell and gene therapy market.

Last updated: March 10, 2026

Bull (30%)+250%

64x Bio's AAV Apex Suite gains rapid adoption, securing key partnerships with major gene therapy companies and expanding its platform to new therapeutic areas. Revenue scales to $75M by 2028, justifying a $1.6B valuation at a 21x revenue multiple, driven by strong IP and critical bottleneck solution.

Base (40%)+50%

Continued adoption of VectorSelect and AAV Apex Suite leads to moderate revenue growth, reaching $18M by 2028. The company secures additional funding at a $675M valuation, reflecting steady progress in a competitive market.

Bear (30%)-75%

Incumbents or well-funded competitors launch similar or superior cell line optimization platforms, eroding 64x Bio's market share and pricing power. Revenue growth stalls, leading to a down round at a $110M valuation, significantly impacting common stock value due to $59.6M in liquidation preferences.

Est. time to liquidity~3.0 years

Preference Stack Risk

moderate

Investors hold $59.6M in liquidation preferences. In an exit at or below the estimated $450M valuation, common stock holders would receive value only after this amount is paid out.

Dilution Risk

high

As a Series A company with high capital intensity, 64x Bio will likely require additional funding rounds, which could lead to further dilution for existing equity holders.

Secondary Liquidity

none

There is no indication of active secondary markets or tender offers for 64x Bio's shares at this early stage.

Questions to Ask at the Interview

Strategic questions based on 64x's data — designed to show you've done your homework.

  • 1

    “With the launch of AAV Apex Suite, how is 64x Bio strategically positioning itself against larger players like Cytiva or potential in-house solutions from major biopharma companies to maintain its competitive moat?”

  • 2

    “Given the current estimated annual revenue of $3.6M and the significant TAM, what are the key milestones and revenue targets the company aims to achieve in the next 24 months to justify its valuation and attract future funding?”

  • 3

    “Considering the company's Series A stage and total funding of $59.6M, what is the anticipated timeline for a liquidity event (IPO or acquisition), and how does the company plan to manage potential future dilution for employees?”

Community

Valuation Sentiment

Our model estimates -60% upside. What do you think?

Anonymous. Do not share material non-public information.

Community Discussion

Comments are reviewed before they appear publicly.

0/2000

Loading comments...

Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.